Ibrutinib/Venetoclax Yields Long-Term Efficacy in Japanese R/R MCL Trial
Over 80% of a small cohort of patients with mantle cell lymphoma achieved a complete response to ibrutinib plus venetoclax.
How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025
Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
Nadunolimab Exhibits Comparable Efficacy Vs Chemotherapy Alone in TNBC
The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.
Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center
Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.
FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy
Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.
ASH 2025: Key Anticipated Updates in the Leukemia Landscape
Updated results at ASH 2025 may support new alternatives to continuous therapy and standard intensive chemotherapy across different leukemia types.
